ECOVAXXIN® MS EU marketing authorisation granted

Summary by AI ^BETAClose X

ECO Animal Health Group plc has received EU marketing authorisation for its poultry vaccine ECOVAXXIN® MS, which targets Mycoplasma synoviae infections and aims to reduce air-sac and foot-pad lesions and egg production losses, potentially impacting laying hens by 5-10%. This authorisation was granted over a month earlier than expected, following a positive opinion in November 2025, and represents the first commercial launch from the company's R&D portfolio. ECO Animal Health plans to provide further details on the EU commercial launch in early 2026.

Disclaimer*

Eco Animal Health Group PLC

22 December 2025

A green and white sign with black text AI-generated content may be incorrect.

ECO Animal Health Group plc

("ECO" or the "Company")

EU marketing authorisation granted for ECOVAXXIN® MS

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that the European Commission has adopted a decision granting EU marketing authorisation (MA) for ECOVAXXIN® MS, the Company's poultry vaccine against Mycoplasma synoviae.

The MA has been issued over a month earlier than anticipated following the Committee for Medicinal Products for Veterinary Use's Positive Opinion in November 2025.

ECOVAXXIN® MS provides active immunisation of future layer and breeder chickens from four weeks of age, helping to reduce air-sac and foot-pad lesions and egg production losses caused by Mycoplasma synoviae infections. The infection causes economic loss, especially in laying hens, and the number of eggs produced by affected layers can be reduced by 5-10%.

The Company will issue an update to the market in early 2026 to provide further details on its plans for the EU commercial launch of ECOVAXXIN® MS.

David Hallas, Chief Executive Officer of ECO Animal Health, said: "We are delighted to have received EU marketing authorisation for ECOVAXXIN MS, over a month ahead of schedule. This is a key milestone for ECO, enabling the first commercial launch from our innovative R&D portfolio, and reflects the high-quality work from our R&D, regulatory, marketing, and technical teams.

"We look forward to updating the market early in 2026 to provide more detail on our plans for the commercial launch of this important vaccine."

-Ends-

Contacts

ECO Animal Health Group plc

David Hallas (Chief Executive Officer)

Christopher Wilks (Chief Financial Officer)

020 8447 8899

ICR Healthcare (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

Singer Capital Markets (Nominated Adviser & Joint Broker)

Philip Davies

Samed Ethemi

020 7496 3000

Panmure Liberum (Joint Broker)

Emma Earl

Will Goode

Mark Rogers

Rupert Dearden

020 3100 2000

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin^® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

Click here for more information: https://ecoanimalhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END